Search results for "Vaccination."

showing 10 items of 654 documents

Pertussis: Microbiology, Disease, Treatment, and Prevention

2016

SUMMARY Pertussis is a severe respiratory infection caused by Bordetella pertussis , and in 2008, pertussis was associated with an estimated 16 million cases and 195,000 deaths globally. Sizeable outbreaks of pertussis have been reported over the past 5 years, and disease reemergence has been the focus of international attention to develop a deeper understanding of pathogen virulence and genetic evolution of B. pertussis strains. During the past 20 years, the scientific community has recognized pertussis among adults as well as infants and children. Increased recognition that older children and adolescents are at risk for disease and may transmit B. pertussis to younger siblings has undersc…

0301 basic medicineMicrobiology (medical)MaleBordetella pertussismedicine.medical_specialtyEpidemiologyWhooping Cough030106 microbiologyReviewsDiseaseDisease Outbreaks03 medical and health sciences0302 clinical medicineImmunityEpidemiologymedicineHumans030212 general & internal medicineWhooping coughImmunity CellularGeneral Immunology and Microbiologybiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthOutbreakRespiratory infectionmedicine.diseasebiology.organism_classificationVaccinationInfectious DiseasesEarly DiagnosisImmunologyFemalebusiness
researchProduct

Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers …

2018

To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with…

0301 basic medicineMicrobiology (medical)MalePediatricsmedicine.medical_specialty030106 microbiologyImmunization SecondaryBooster doseAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccines03 medical and health sciences0302 clinical medicineImmunogenicity VaccineSuspensionsGermanyTetanus ToxoidMedicineHumansHepatitis B Vaccines030212 general & internal medicineVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesImmunization ScheduleCzech RepublicHaemophilus VaccinesBooster (rocketry)business.industryDiphtheriaImmunogenicityVaccinationInfant NewbornInfantmedicine.diseaseRotavirus vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesPneumococcal vaccinePediatrics Perinatology and Child HealthFemalebusinessThe Pediatric infectious disease journal
researchProduct

Influenza vaccination of healthcare workers in Italy: could mandatory vaccination be a solution to protect patients?

2019

Several studies have reported that influenza infections in healthcare workers (HCWs) can lead to nosocomial outbreaks. HCWs can potentially be infected with influenza every year, and may continue to work, encouraging the spread of the virus. Different strategies, such as informative interventions on influenza and influenza vaccination, ‘onsite’ vaccination weeks, communicative strategies through dedicated web and social media pages, and mandatory informed dissent form, were organized for HCWs working at the University Hospital of Palermo, during previous influenza seasons. However, the increased vaccination rates observed among HCWs still remain far from the 75% recommended by Public Healt…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyVaccination CoverageAttitude of Health Personnelhealth care facilities manpower and servicesHealth Personneleducation030106 microbiologyPsychological interventionMandatory ProgramsSettore MED/42 - Igiene Generale E ApplicataMicrobiologyInfectious Disease Transmission Professional-to-PatientHospitals University03 medical and health sciencesHealth careInfluenza HumanmedicineHumansNosocomial outbreakbusiness.industryPublic healthVaccinationvirus diseasesUniversity hospitalMandatory vaccinationcommunication strategies healthcare workers influenza disease perception influenza vaccination mandatory vaccinationVaccination030104 developmental biologyItalyInfluenza VaccinesFamily medicinebusinessFuture microbiology
researchProduct

2018

In this study we analysed the effects of prophylactic biolistic DNA vaccination with plasmids encoding the encephalitogenic protein myelin oligodendrocyte glycoprotein (MOG) on the severity of a subsequently MOGp35-55-induced EAE and on the underlying immune response. We compared the outcome of vaccination with MOG-encoding plasmids alone or in combination with vectors encoding the regulatory cytokines IL-10 and TGF-s1, respectively. MOG expression was restricted to skin dendritic cells (DCs) by the use of the DC-specific promoter of the fascin1 gene (pFscn-MOG). For comparison, the strong and ubiquitously active CMV promoter was employed (pCMV-MOG), which allows MOG expression in all trans…

0301 basic medicineMultidisciplinaryT cellExperimental autoimmune encephalomyelitishemic and immune systemsSpleenTransfectionBiologymedicine.diseasenervous system diseasesDNA vaccinationImmune toleranceMyelin oligodendrocyte glycoprotein03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureImmune systemnervous systemimmune system diseasesImmunologymedicinebiology.protein030215 immunologyPLOS ONE
researchProduct

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

2017

T cells directed against mutant neo-epitopes drive cancer immunity. However, spontaneous immune recognition of mutations is inefficient. We recently introduced the concept of individualized mutanome vaccines and implemented an RNA-based poly-neo-epitope approach to mobilize immunity against a spectrum of cancer mutations. Here we report the first-in-human application of this concept in melanoma. We set up a process comprising comprehensive identification of individual mutations, computational prediction of neo-epitopes, and design and manufacturing of a vaccine unique for each patient. All patients developed T cell responses against multiple vaccine neo-epitopes at up to high single-digit p…

0301 basic medicineMultidisciplinarybiologybusiness.industryMelanomaT cellmedicine.medical_treatmentCancerImmunotherapymedicine.diseaseVaccination03 medical and health sciences030104 developmental biologymedicine.anatomical_structureImmunityImmunologymedicineCancer researchbiology.proteinAntibodyNivolumabbusinessNature
researchProduct

Abstract CT034: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent melanoma immunotherapy

2017

Abstract Therapeutic vaccination with tumor antigen-encoding RNAs by local administration is currently being successfully employed in various clinical trials. Advancing from local to more efficient systemic targeting of antigen-presenting cells (APCs), we have developed pioneering RNA-lipoplex (RNA(LIP)) immunotherapeutics for intravenous application based on the employment of well-known lipid carriers without the need for functionalization of particles with molecular ligands. The novel RNA(LIP) formulation has been engineered to preserve RNA integrity after intravenous injection and physicochemically optimized for efficient uptake and expression of the encoded antigen by APCs in various ly…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryImmunogenicitymedicine.medical_treatmentCancer02 engineering and technologyImmunotherapy021001 nanoscience & nanotechnologymedicine.diseaseClinical trialVaccination03 medical and health sciences030104 developmental biologyOncologyTolerabilityAntigenInternal medicinemedicineCancer vaccine0210 nano-technologybusinessCancer Research
researchProduct

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy

2018

ABSTRACT The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe’s largest meeting series of its kind, took place in Mainz, Germany from 15–17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto “Pushing Frontiers in Cancer Immunotherapy”. This meeting report is a summary of some of the CIMT 2018 highlights.

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumansPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryVaccinationCIMTcellular therapyCongresses as TopicXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologycheckpoint blockadeDrug Therapy CombinationImmunotherapybusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2016: Mechanisms of efficacy in cancer immunotherapy — Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10–12 2…

2016

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineantibodiestumor microenvironmentImmunology and AllergyMedicinetumor vaccinationPersonalized therapypersonalized therapyPharmacologyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologycheckpoint blockadebusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

2015

The 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) brought together more than 800 scientists in Mainz, Germany, from May 11–13, 2015, to present and discuss current research...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicinemedicineImmunology and Allergytumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologybusinessHuman Vaccines & Immunotherapeutics
researchProduct

CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy

2017

The 15th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) took place May 10–11, 2017, Mainz, Germany during which scientists and CIMT members from all over the world not only celeb...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyPhysiologyMeeting Reportcombination therapyCell therapy03 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicinemedicineImmunology and Allergyantibodiestumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapycancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biology030220 oncology & carcinogenesischeckpoint blockadebusinessHuman Vaccines & Immunotherapeutics
researchProduct